Benzinga | Dec 15, 2021 08:19AM EST

Pyxis To Be Added To Russell 2000 Index As Of Dec. 20, 2021

Pyxis Oncology, Inc. (NASDAQ:PYXS), a preclinical oncology company focused on developing next-generation therapeutics for difficult to treat cancers, today announced that the company will be added to the Russell 2000(r) Index, effective after the U.S. market opens on December 20, 2021, according to the preliminary list of IPO additions to the Russell indexes. Membership in the Russell 2000 Index, which remains in place until the next reconstitution, is based on membership in the broad-market Russell 3000(r) Index. The stock will also be automatically added to the appropriate growth and value indexes.



"The addition of Pyxis to the Russell 2000 Index drives further momentum following the successful completion of our IPO in October," said Lara Sullivan, M.D., Chief Executive Officer of Pyxis. "Our strong balance sheet supports the continued advancement of our multi-asset multi-platform pipeline into clinical trials in addition to our strategic business development initiatives. At Pyxis, we are fiercely dedicated to improving the lives of patients with difficult to treat cancers, and we look forward to engaging a broader investor base with our inclusion in the Russell 2000 Index."

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell 2000(r) Index and the 3Q21 Russell indexes IPO additions, go to the "Russell US Index IPO additions" section on the FTSE Russell website.